BOULDER, Colo., March 14 /PRNewswire-FirstCall/ -- Tapestry
Pharmaceuticals, Inc. (Nasdaq: TPPH) today announced that it will present
new data at the 2007 American Association for Cancer Research (AACR) Annual
Meeting, April 14-18 in Los Angeles, Calif. Scientists from Tapestry
Pharmaceuticals will discuss preclinical data on the Company's lead
compound, TPI 287, in a poster presentation entitled, "TPI 287 crosses the
blood brain barrier and contributes to antitumor activity in the U251
glioblastoma intracranial tumor model in nude mice." The poster (#1441)
will be presented Sunday, April 15, 2007 from 1:00 - 5:00 p.m. at the
Experimental and Molecular Therapeutics 8 session.
About TPI 287
TPI 287, a proprietary next generation taxane, is Tapestry's lead
clinical compound. This compound was designed to overcome multi-drug
resistance in solid tumors that have become resistant to taxane therapy. In
preclinical testing, TPI 287 demonstrated the ability to inhibit tumor cell
growth in a number of in vitro cell lines and in general, has shown
equivalent inhibition of tumors in certain animal xenograft models when
tested against standard comparative agents. In some cell lines resistant to
taxanes, TPI 287 has demonstrated greater inhibition of tumors in certain
animal xenograft models when tested against standard comparative agents.
The in vitro activity was seen across multiple cell lines including cell
lines known to be sensitive to taxanes and cell lines known to be resistant
to taxanes. Taxane sensitive cell lines in which TPI 287 has shown activity
include cell lines derived from breast cancer, uterine cancer and non-small
cell lung cancer. Taxane resistant cell lines in which TPI 287 shows
greater activity include lines derived from breast and colon cancer. In in
vivo testing TPI 287 demonstrated greater tumor growth inhibition activity
in tumor cell lines with multiple drug resistance, MDR1.
TPI 287 is currently in clinical studies in the United States. Tapestry
plans to initiate multiple Phase II trials for TPI 287 in 2007.
About Tapestry Pharmaceuticals, Inc.
Tapestry Pharmaceuticals, Inc. is a company focused on the development
of proprietary therapies for the treatment of cancer. For more information
about Tapestry and its technologies, visit Tapestry's web site at
http://www.tapestrypharma.com.
Forward-Looking Statements
Statements in this press release that are not historical facts are
"forward-looking statements" that involve risks and uncertainties. Forward-
looking statements can be identified by the use of words such as
"opportunities," "trends," "potential," "estimates," "may," "will,"
"should," "anticipates," "expects," "hopes" or comparable terminology or by
discussions of strategy. Such forward-looking statements include the
statements that the Company will initiate Phase II intravenous studies of
TPI 287 into the clinic in 2007. Such statements involve known and unknown
risks, uncertainties and other factors that may cause our actual results,
performance or achievements to be materially different from the results,
performance or achievements expressed or implied by such forward-looking
statements. Such risks, uncertainties and other factors include risks that
clinical trials for TPI 287 will be delayed due to institutional approvals,
patient recruitment, formulation and manufacturing difficulties, delays in
finalizing and receiving approval of Phase II protocols, negotiations with
regulatory agencies, or other factors; that human clinical trials may show
that TPI 287 is unsafe and/or ineffective in treating cancer in humans.
General implementation risks associated with development of TPI 287 include
those that we are blocked or limited in the development of TPI 287 because
of the intellectual property rights of third parties; that we are limited
in our ability to obtain, maintain and enforce our own intellectual
property; that development of TPI 287 is delayed or terminated because the
costs of further development exceed its value; and that the Company's
resources will be insufficient to continue development. Additional risks,
uncertainties and other factors are identified under the captions "Risk
Factors" and "Special Note Regarding Forward-Looking Statements" in the
Company's reports filed from time to time with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the year ended
December 27, 2006. The Company disclaims any intention or obligation to
update publicly or revise any forward-looking statements, whether as a
result of new or additional information, future events or otherwise.
Contact: Tapestry Pharmaceuticals, Inc.
Gordon Link
Senior Vice President, Chief Financial Officer
303-516-8500
glink@tapestrypharma.com
Elma Hawkins, Ph.D.
Communications and Corporate Development
212-400-3019
ehawkins@tapestrypharma.com
Investor: Lilian Stern
Stern Investor Relations, Inc.
212-362-1200
lilian@sternir.com
Media: Lloyd Benson/Dana Conti
Schwartz Communications
781-684-0770
tapestry@schwartz-pr.com
SOURCE Tapestry Pharmaceuticals, Inc.
 back to top
Related links:
http://www.tapestrypharma.com
http://www.prnewswire.com/comp/936204.html /
CONTACT:
Gordon Link, Senior Vice President, Chief
Financial Officer, +1-303-516-8500, glink@tapestrypharma.com, or
Elma Hawkins, Ph.D., Communications and Corporate Development,
+1-212-400-3019, ehawkins@tapestrypharma.com, both of Tapestry
Pharmaceuticals, Inc., or Lilian Stern, Stern Investor Relations,
Inc., +1-212-362-1200, lilian@sternir.com, or Lloyd Benson or
Dana Conti, Schwartz Communications, +1-781-684-0770,
tapestry@schwartz-pr.com
|
